Related Experiment Video
Updated: Feb 15, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.6K
CMV Pneumonitis following Bendamustine containing Chemotherapy
Sumeet Vimal Kishor Singhania1, Pujan Parikh2, Sandeep Goyle3
1Consultant, Pulmonary Medicine.
The Journal of the Association of Physicians of India
|January 10, 2018
Summary
Bendamustine use in lymphoma patients may increase Cytomegalovirus (CMV) reactivation risk. This case highlights CMV pneumonitis presenting as fever, emphasizing the need for vigilance in patients on bendamustine.
Area of Science:
- Oncology
- Infectious Diseases
Background:
- Bendamustine is increasingly utilized for indolent lymphoma treatment.
- Emerging data suggests a potential link between bendamustine and adverse events, including Cytomegalovirus (CMV) reactivation.
Observation:
- A case of CMV pneumonitis is presented in a lymphoma patient undergoing bendamustine therapy.
- The patient initially presented with unexplained pyrexia.
Findings:
- The CMV pneumonitis responded effectively to intravenous Ganciclovir treatment.
- This case underscores the possibility of CMV reactivation in patients receiving bendamustine.
Implications:
- Clinicians should maintain a high index of suspicion for CMV reactivation in lymphoma patients on bendamustine presenting with pyrexia or respiratory symptoms.
- Early recognition and treatment with antiviral agents like Ganciclovir are crucial for favorable outcomes.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
802
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
802
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
932
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
932
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
715
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
715
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
652
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
652